glucocorticoid receptor antagonist Archives

Can Corcept’s Lifyorli become a real new standard in platinum-resistant ovarian cancer after FDA approval?

By Pallavi Madhiraju on March 26, 2026 Pharma & Biotech

Corcept’s Lifyorli won FDA approval in platinum-resistant ovarian cancer. Read what the survival data could change for clinicians, rivals, and regulators.

Corcept’s relacorilant CRL leaves endocrinology ambitions in limbo as oncology pivot takes center stage

By Pallavi Madhiraju on January 1, 2026 Pharma & Biotech

Find out why FDA’s complete response letter for Corcept’s relacorilant could reshape treatment of hypercortisolism, with implications for oncology approval.